Loading...
Market
What will be Briumvi's sales revenue in 2025?
3
Resolution / Starting Odds
$500 million to $1 billion • 25%
Less than $500 million • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Financial reports and earnings releases from TG Therapeutics
Story
TG Therapeutics ($TGTX) Reports Positive ENHANCE Phase 3b Data on Briumvi for Multiple Sclerosis
Oct 14, 2024, 11:37 AM
TG Therapeutics ($TGTX) has released new data from its ENHANCE Phase 3b study, showing that rapid 30-minute infusions of Briumvi (ublituximab-xiiy) are well tolerated in patients with relapsing forms of multiple sclerosis. This comes amid comparisons with SubQ Ocrevus, which requires a 10-minute delivery of 23ml of fluid under the skin, potentially causing discomfort and bruising. The total treatment time for SubQ Ocrevus is approximately 1.5 hours, compared to 4.5 hours for IV Ocrevus. KOLS do not favor SubQ Ocrevus, and the Briumvi switching trial is showing promising results.
View original story
Similar markets
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $200 million • 25%
More than $200 million • 25%
Less than £10 million • 33%
£10 million to £30 million • 34%
More than £30 million • 33%
Below $60 billion • 25%
$60 billion to $70 billion • 25%
$70 billion to $80 billion • 25%
Above $80 billion • 25%
Below $41.3 billion • 25%
$41.3 billion to $41.5 billion • 25%
$41.6 billion to $41.9 billion • 25%
Above $41.9 billion • 25%
Less than $50M • 25%
$50M to $99M • 25%
$100M to $149M • 25%
$150M or more • 25%
Less than $100 million • 25%
$100 million to $200 million • 25%
$200 million to $300 million • 25%
More than $300 million • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%
Under 20% • 25%
20%-40% • 25%
40%-60% • 25%
Over 60% • 25%
Less than $500 million • 25%
$500 million - $700 million • 25%
$700 million - $900 million • 25%
More than $900 million • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%